

Barcelona, October 27th 2015

SIGNIFICANT EVENT

DIVESTMENT OF CONSTELLA®/LINZESS® TO ALLERGAN

Almirall, S.A. (ALM.MC), as per section 82 of the Securities Market Act (Ley 24/1988 on 28 July, that regulates the Stock Market or *Mercado de Valores* in Spain) and other applicable provisions, hereby announces that:

Almirall, with the agreement of Ironwood Pharmaceuticals, has decided to divest the rights of Constella®/Linzess® to Allergan. The total amount of the transaction is 64 million euros. Following this agreement Almirall will no longer be involved with this product.

The transaction has no impact on our EBIT Guidance for 2015. An exceptional income of around 35 million euros (net of tax and write-downs) will be allocated to net profit in the fourth-quarter results of Almirall.

Both companies will work diligently to ensure a smooth transition of the product without disruption to patients.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations Department
inversores@almirall.com

